Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | SGN-35T |
| Synonyms | |
| Therapy Description |
SGN-35T is an antibody-drug conjugate (ADC) comprising an anti-TNFRSF8 (CD30) antibody conjugated to monomethyl auristatin E (MMAE) via a D-leucine-alanine-glutamate linker, which potentially induces cell cycle arrest and inhibits tumor growth (Mol Cancer Ther (2023) 22 (12_Supplement): C132). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| SGN-35T | PF-08046045|PF 08046045|FP 08046045|SGN35T|SGN 35T | SGN-35T is an antibody-drug conjugate (ADC) comprising an anti-TNFRSF8 (CD30) antibody conjugated to monomethyl auristatin E (MMAE) via a D-leucine-alanine-glutamate linker, which potentially induces cell cycle arrest and inhibits tumor growth (Mol Cancer Ther (2023) 22 (12_Supplement): C132). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06120504 | Phase I | SGN-35T | A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers | Active, not recruiting | USA | ESP | 0 |